of NO synthesized from l-arginine are regulated by constitutive, lowoutput isoforms of NO synthase, eNOS (endothelial NOS) and nNOS (neuronal NOS), inducible, high-output NO synthase (iNOS) and the activity of endogenous inhibitors of NOS such as symmetric (SDMA) or asymmetric dimethylarginine (ADMA). [17] [18] [19] [20] [21] [22] There is also evidence that the l-arginine/NO/ADMA pathway plays an important role in the development of cardiovascular disorders including I/R. 14, [17] [18] [19] [20] [21] In 2012, Wang et al showed that 5-phenyloxyphenyl-5-aminoalkyl nitrate barbiturate hybrid ( Figure 1 ) inhibits the secretion of MMP-2 and MMP-9 from cells and this effect depends on the release of NO from this compound. 23 As changes in the bioactivity of the MMP-2 and NO pathways may underlie I/R injury, we suggested that the administration of hybrid may normalize the levels of MMP-2 and NO and ameliorate the impact of I/R on the heart.
We report that this compound has the ability to protect hearts subjected to I/R injury and improve the mechanical function by inhibition of MMP-2 and restoration of physiological levels of NO.
| MATERIAL S AND ME THODS
This investigation conforms to the Guide to the Care and Use of Experimental Animals published by the Polish Ministry of Science and Higher Education. This study was approved by the Ethics
Committee for Experiments on Animals at the Ludwik Hirszfeld
Institute of Immunology and Experimental Therapy Polish Academy of Sciences, Wroclaw, Poland.
| Cell culture
The primary Human cardiac myocytes (HCM) from ScienCell
Research Laboratories (Carlsbad, CA, USA) were cultured in
Dulbecco's Modified Eagle's Medium containing Cardiac Myocyte
Growth Supplement (ScienCell Research Laboratories), 5% fetal bovine serum, 100 U/mL penicillin, 100 µg/mL streptomycin (all from Sigma-Aldrich, St. Louis, MO, USA). The cells were cultured at 37°C in a water-saturated, 5% CO 2 atmosphere. Cells were passaged at 80%
confluence by harvesting with 0.25% trypsin-EDTA (Sigma-Aldrich).
| The I/R of human cardiac myocytes in culture
Human cardiac myocytes underwent in vitro chemical I/R as proposed in Ref. 24 . Briefly, following 15 minutes aerobic stabilization, the cells were subjected to 9 minutes chemical ischaemia using an inhibitor of cellular respiration and 20 minutes aerobic reperfusion. Cells were subjected to aerobic stabilization and reperfusion . It was determined that 9 minutes of ischaemia was optimal to follow cell recovery during I/R injury (data not shown). At the end of aerobic incubation, the cells were centrifuged for 1 minute at 1500×g at RT and the pellet was suspended in the ischaemia buffer and incubated for 9 minutes at RT. Then the buffer was removed by centrifugation at 1500×g at RT and the pellet was resuspended in the reperfusion HEPES buffer containing additional 55 µmol/L CaCl 2 and 0.75 mg/mL mg BSA and incubated for 20 minutes at RT temperature. After reperfusion, the myocytes were centrifuged at 1500×g for 5 minutes at RT and the pellet was homogenized and the resultant homogenate stored until assayed at −80°C. In aerobic control experiments, the myocytes were aerobically maintained for the duration of the experiment. In I/R experiments examining the effect of barbiturate, the cells were subjected to I/R in the presence of increasing concentrations of the tested compound (0.1, 1.0 and 10 μmol/L) for 10 minutes before ischaemia and for first the 10 minutes of I/R.
| Cell homogenization
Cells were suspended in the homogenization buffer (50 mmol/L Tris-HCl (pH 7.4) containing 3.1 mmol/L sucrose, 1 mmol/L DTT, 10 µg/mL leupeptin, 10 µg/mL soybean trypsin inhibitor, 2 µg/mL aprotinin and 0.1% Triton X-100) and homogenized by three cycles of freezing (in liquid nitrogen) and thawing (at 37°C) and then homogenized mechanically (three times for 10 seconds) using a hand-held homogenizer on ice. Homogenates were centrifuged at 10 000×g, F I G U R E 1 Constitutional formula of 5-phenyloxyphenyl-5-aminoalkyl nitrate barbiturate for 5 minutes at 4°C and the supernatants were immediately transferred into a fresh tube and stored at −80°C for further biochemical analysis. genes was compared in cells that were exposed to aerobic conditions and cells subjected to I/R and I/R with the addition of appropriate concentration of the tested substance.
| MMP-2, MMP-9 and iNOS mRNA expression

| Langendorff isolated heart perfusion
Wistar rats weighing 300-350 g were used in these experiments as a surrogate model for analysis of cardioprotection. 24 The hearts were excised from animals treated with buprenorfin (0.02 mg/kg, ip) and anaesthetized with sodium pentobarbital (40 mg/kg, ip).
Spontaneously beating isolated hearts rinsed by immersion in ice-cold
25 mmol/L NaHCO 3 , 11 mmol/L glucose, and 0.5 mmol/L EDTA, pH 
| Global I/R of isolated rat hearts
After 25 minutes of aerobic perfusion, the hearts were subjected 
| Heart perfusion for cardiomyocytes isolation
The hearts were rapidly excised from rats anaesthetized with sodium pentobarbital (40 mg/kg, ip) as described above. Spontaneously beating 
| Isolation of ventricular cardiomyocytes
After 5 minutes of heart perfusion (in Langendorff system) with MIB containing 1 mmol/L CaCl 2 , the buffer was replaced with MIB con- 
| Chemical ischaemia of isolated ventricular cardiomyocytes
Chemical 
| Measurement of ventricular cardiomyocytes' contractility
The contractility of cardiomyocytes was measured at the end of the 
| Preparation of heart homogenates
Hearts previously frozen at −80°C were crushed using a mortar The difference between RPP in 25 and 77 minutes of the experiment. d ANOVA test; *P < 0.05 vs Aerobic; # P < 0.05 vs I/R20; n = 5-10; Aero-aerobic control; I/R20-ischaemia/reperfusion control.
leupeptin, 10 mg/mL soybean trypsin inhibitor, 2 mg/mL aprotinin and 0.1% Triton X-100. The homogenate was centrifuged at 10 000×g at 4°C for 15 minutes and the supernatant was collected and stored at −80°C.
| Determination of protein concentration
Protein concentration in the cardiac tissue homogenates was determined using Bradford method (BioRad) and BSA (heat shock fraction, ≥98%, Sigma-Aldrich) served as the protein standard.
| MMP-2 and MMP-9 protein level in heart homogenates
MMP-2 and MMP-9 in hearts homogenates were measured using Zymograms were scanned using VersaDoc 5000 (BioRad) and the band intensities were analyzed using Quantity One software v. 4.6.6 (BioRad).
MMP activities were expressed as activity per microgram of protein.
| Analysis of iNOS by immunoblotting
iNOS tissue expression in heart homogenates was determined using
Western Blot. An aliquot of 60 µg of total proteins from heart homogenates was separated on 12% SDS-PAGE. iNOS transferred on PVDF membrane (Bio-Rad) was detected with mouse anti-iNOS polyclonal antibody 1:5000 (Abcam, ab 21775) and secondary goat anti-mouse IgG horseradish peroxidase conjugate 1:1000 (Bio-Rad). For protein detection, the ClarityTM Western ECL substrate (Bio-Rad) was used.
ChemiDocTM MP System and Quantity One Software (Bio-Rad) were used for detection of bands and measurement of their density. iNOS was expressed as AU in ratio to beta-tubulin (Abcam, ab 108342).
| Measurement of endogenic rat asymmetrical dimethylarginine (ADMA)
Endogenous asymmetrical dimethylarginine (ADMA) concentration in rat heart homogenates was assessed using Rat ADMA Elisa Kit was used (Cusabio, Houston, TX, USA). Briefly, the assay is based on competitive inhibition enzyme immunoassay technique.
Goat-anti-rabbit antibodies were used to bind ADMA from cardiac tissue or labelled ADMA. Then, the antigen was detected by antibodies specific for labelled and unlabelled antigen. ADMA content in tissue homogenates was expressed as ng/mg of total protein.
| Nitrate/nitrite assessment
Quantitative Nitric Oxide Assay Kit (Abcam, Cambridge, MA, USA) was used to determine the amount of total nitrate and nitrite in heart homogenates (oxidative products of endogenous NO in the tissue) which served as a measure of NOS activity (NO production), as previously described. 14 Briefly, the homogenates were diluted 1:1 with deionized water and then deproteinized using centrifugal ultrafiltration. Ultrafiltrates were analysed for total nitrate and nitrite content. In two-step reaction, the nitrates were converted into nitrites by nitrate reductase and then the nitrites were coupled into a coloured azo compound with maximum absorbance at 540 nm. NO content in hearts was expressed as nmol/L per mg of total protein.
| Assessment of LDH activity
Lactate Dehydrogenase Activity Assay Kit (Sigma-Aldrich) was used to determine the activity of LDH in rat hearts following the manufacturer's instructions. Briefly, lactate dehydrogenase interconverts pyruvate and lactate with the reduction of NAD to NADH, which is detected with a colorimetric assay at 450 nm. Lactate dehydrogenase served as a marker of cell damage, because of its cytoplasmic location and immediate release into extracellular space due to membrane damage/permeability. 
| Analysis of MLC1 in heart homogenates
| Statistical analysis
GraphPad Prism v. 7 was used to perform the statistical analysis.
Statistical analysis was performed with one-way ANOVA with Results were expressed as mean ± SEM P < 0.05 was the criterion for statistical significance.
| RE SULTS
| Effects of 5-phenyloxyphenyl-5-aminoalkyl nitrate barbiturate on mechanical function, coronary blood flow and heart injury
Mechanical heart function, CF, LVDP and HR were significantly decreased in hearts subjected to 22 minutes of global no-flow ischaemia followed by 30 minutes of reperfusion in comparison to aerobic hearts ( Table 1 ). The 5-phenyloxyphenyl-5-aminoalkyl nitrate barbiturate (1-10 µmol/L) resulted in concentration-dependent recovery of mechanical function in comparison to aerobic control ( Figure 3A ).
An infusion of barbiturate also improved the CF and HR.
Rat cardiomyocytes contractility, expressed as a peak shortening (% of cell length), was significantly decreased (>57%) in cells subjected to in vitro I/R in comparison to cardiomyocytes subjected to aerobic conditions ( Figure 3B ). Barbiturate treatment protected cell contractility in a concentration-dependent manner. 5-phenyloxyphenyl-5-aminoalkyl nitrate barbiturate at 10 µmol/L concentration resulted in the full protection of contractility. Figure 3C shows that changes in LDH content (a marker of cellular injury) in the myocardial tissue during I/R The barbiturate treatment led to concentration-dependent decrease in LDH release from the heart.
| An influence of MMP-2-inhibitor-NO-donor hybrid on expression of MMP-2, MMP-9 and iNOS genes
To assess if the hybrid affects expression of MMP-2 and MMP-9 as well as iNOS genes, specific mRNA and corresponding protein expression Figure 5C ). Degradation of MLC1 in the heart tissue negatively correlated with increased activity of MMP-2 ( Figure 5D ).
| 5-phenyloxyphenyl-5-aminoalkyl nitrate barbiturate as a donor of NO
The next aim of this study was to evaluate whether an infusion of the hybrid as a donor of NO, into hearts subjected to I/R, may affect the synthesis of inducible form of NOS (iNOS), ADMA. We have observed decreased tissue content of NO (showed as total nitrite/ nitrate content) during I/R and an increased tissue NO during perfusion with barbiturates ( Figure 6A ). An infusion of NO donor also led to significant reduction of iNOS and ADMA, more than 48% and 46% respectively ( Figure 7A-B) . The analysis of correlations showed that iNOS positively correlated with production of ADMA ( Figure 7C ) and iNOS negatively correlated with NO content ( Figure 6B ).
| D ISCUSS I ON
It is well established that cardiac I/R injury results in microvascular damage or myocardial stunning. 3, 27, 28 Although the complete molecular basis for myocardial injury following I/R is not fully understood, it is known that degradation of contractile proteins and inadequate blood supply contribute to the pathogenesis of this injury. Hypoxic injury of the cardiovascular system is one of the most frequent complications following ischemic state. 32 The deprivation of oxygen and nutrient supply results in a series of sudden biochemical and metabolic changes within the myocardium leading to cell death. 2, 33 The goal of reoxygenation/reperfusion is to restore the proper oxygen supply in hypoxic tissues to salvage viable myocardium. However, reperfusion leads to an acute increase in oxidative stress, which triggers a cascade of pathophysiological events that can paradoxically induce myocardial injury, thereby mitigating the full benefits of reperfusion in terms of myocardial infarction size reduction. 33, 34 There are several hypotheses regarding the mechanism of I/R injury. Some assume a pivotal role for increased production of ROS 13 and enhanced post-translational modifications of proteins which are then more susceptible to proteolytic degradation 29 and uncontrolled activation of MMPs. 15 MMPs are a family of more than 25 proteolytic enzymes with similar substrate specificity that play many important roles in a variety of physiological and pathological processes. 35 MMP-2 is found in almost all tissue types and degrades collagens as well as other extracellular matrix proteins. Enhanced MMP activity is implicated in pathological states in the cardiovascular system including atherosclerosis, restenosis, ischemic heart disease and heart failure. [35] [36] [37] [38] [39] There are also studies showing that increased activation of MMPs in hearts subjected to I/R is a key factor of impaired mechanical function of the heart 15 and I/R injury. 8, 11, 15, 29, 32, 40, 41 As increased sarcomere it is responsible for proper heart contractile function.
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Therefore, inhibition of MMP-2 activity and MLC proteolysis could be the main causation of improved heart function in our model.
It has been well established that the restoration of blood flow to the myocardium subjected to I/R generates oxidative stress due to an increased formation of reactive oxygen species (ROS) in the ischemic area. 1, 44, 45 Oxidative stress also triggers the increased F I G U R E 8 Potential regulation of MMP-2 and iNOS-ADMA pathway during oxidative stress in the absence (A) and the presence (B) of 5-phenyloxyphenyl-5-aminoalkyl nitrate barbiturate-the scheme. NO is produced by inducible form of nitric oxide synthase (iNOS) from l-arginine in the presence of oxygen, NADPH (nicotinamide adenine dinucleotide phosphate), BH4 (tetrahydrobiopterin) and FMN (flavin mononucleotide) and plays a crucial role in vasodilatation (increasing coronary flow-CF), leukocytes adhesion, platelets aggregation and MMP-2 expression. Oxidative stress leads to generation of ROS induced iNOS expression and production of endogenous asymmetric dimethylarginine (ADMA ADMA has been reported to competitively inhibit NO synthesis by displacing l-arginine from NOS. 53 This study confirmed an increased ADMA expression and production in hearts subjected to I/R ( Figure 6 ). As the l-arginine/NO pathway actively participates in the regulation of numerous physiological processes including vasodilation, 54 inhibition of platelet aggregation 55 and leukocyte adhesion, 56 an enhanced ADMA synthesis and decreased NO production could contribute to enhanced tissue damage. Our observations are consistent with other studies, including both animal models and patients, in which enhanced ADMA levels correlated with pulmonary hypertension, hypercholesterolemia and endothelial dysfunction and atherosclerosis. [57] [58] [59] Accumulation of ADMA would be expected to enhance cardiovascular disorders through loss of NO. 17 Moreover, studies in cultured human endothelial cells have shown that elevated ADMA results in the production of O − 2 . As described above, ADMA may uncouple NOS resulting in a switch of the enzymatic activity from NO to ROS production. In turn, an increased production of O − 2 ·leads to an inhibition of N G ,N G -dimethylarginine dimethylaminohydrolase (DDAH), a key enzyme that metabolizes ADMA and enhanced production of toxic peroxynitrite, which activates MMPs 13 and modifies contractile proteins 32 ( Figure 8A ). Interestingly, administration of nitrate hybrid compound into hearts undergoing I/R led to decreased production of ADMA, probably as a consequence of decreased tissue expression of iNOS and supply of exogenous NO ( Figure 8B ).
In conclusion, this study confirms the potential, dual cardioprotective role of an MMP-inhibitory nitrate hybrid compound in the development of I/R injury. We showed that the hybrid compound can suppress MMP-2 mRNA expression and activity, hence limiting injury. Moreover, this compound decreases iNOS and ADMA production thus normalizing the NO bioactivity.
Therefore, 5-phenyloxyphenyl-5-aminoalkyl nitrate barbiturate shows cardioprotective activity and this pharmacological profile could be further explored in pre-clinical and early-clinical investigations.
60
ACK N OWLED G EM ENT
We kindly thank Wrovasc for allowing the Langendorff system apparatus to be rented.
CO N FLI C T O F I NTE R E S T
The authors have no conflicts of interest to disclose.
O RCI D
Iwona Bil-Lula https://orcid.org/0000-0002-2769-0166
